BNP Paribas Financial Markets’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.9M Sell
378,720
-541,756
-59% -$39.1M 0.01% 1014
2026
Q1
$62.7M Buy
920,476
+91,814
+11% +$6.5M 0.03% 576
2025
Q4
$62.9M Buy
828,662
+808,515
+4,013% +$58.8M 0.03% 579
2025
Q3
$1.24M Buy
20,147
+7,243
+56% +$377K ﹤0.01% 2979
2025
Q2
$630K Buy
12,904
+7,329
+131% +$348K ﹤0.01% 3180
2025
Q1
$284K Sell
5,575
-4,717
-46% -$235K ﹤0.01% 3515
2024
Q4
$465K Sell
10,292
-62,654
-86% -$2.68M ﹤0.01% 3355
2024
Q3
$2.71M Sell
72,946
-54,655
-43% -$1.83M ﹤0.01% 1876
2024
Q2
$3.9M Sell
127,601
-72,069
-36% -$2.33M ﹤0.01% 1542
2024
Q1
$5.81M Sell
199,670
-171,910
-46% -$4.82M 0.01% 1362
2023
Q4
$10.2M Buy
371,580
+269,292
+263% +$6.16M 0.01% 1015
2023
Q3
$2.29M Buy
102,288
+45,553
+80% +$1.69M ﹤0.01% 1791
2023
Q2
$2.31M Sell
56,735
-22,122
-28% -$1.08M ﹤0.01% 1668
2023
Q1
$3.82M Buy
78,857
+11,896
+18% +$544K 0.01% 1411
2022
Q4
$2.56M Sell
66,961
-2,961
-4% -$123K ﹤0.01% 1631
2022
Q3
$3.51M Buy
69,922
+36,354
+108% +$1.78M 0.01% 1561
2022
Q2
$1.34M Buy
33,568
+5,367
+19% +$188K ﹤0.01% 2009
2022
Q1
$1.05M Buy
28,201
+13,638
+94% +$525K ﹤0.01% 2283
2021
Q4
$580K Buy
14,563
+2,046
+16% +$78.3K ﹤0.01% 2933
2021
Q3
$466K Buy
12,517
+9,926
+383% +$408K ﹤0.01% 2779
2021
Q2
$110K Sell
2,591
-5,312
-67% -$228K ﹤0.01% 3017
2021
Q1
$374K Sell
7,903
-1,359
-15% -$80.7K ﹤0.01% 2739
2020
Q4
$565K Sell
9,262
-5,351
-37% -$315K ﹤0.01% 2398
2020
Q3
$683K Buy
14,613
+7,925
+118% +$390K ﹤0.01% 2017
2020
Q2
$339K Sell
6,688
-69,126
-91% -$3.4M ﹤0.01% 2255
2020
Q1
$3.38M Buy
75,814
+67,195
+780% +$3.38M 0.01% 1191
2019
Q4
$414K Sell
8,619
-1,751
-17% -$74.4K ﹤0.01% 2569
2019
Q3
$351K Buy
10,370
+3,290
+46% +$143K ﹤0.01% 2401
2019
Q2
$319K Sell
7,080
-4,982
-41% -$197K ﹤0.01% 2311
2019
Q1
$454K Buy
12,062
+11,057
+1,100% +$371K ﹤0.01% 2158
2018
Q4
$34.5K Sell
1,005
-1,558
-61% -$56K ﹤0.01% 2893
2018
Q3
$120K Buy
2,563
+625
+32% +$25.9K ﹤0.01% 2646
2018
Q2
$65.4K Sell
1,938
-6,718
-78% -$209K ﹤0.01% 2998
2018
Q1
$234K Buy
8,656
+198
+2% +$5.02K ﹤0.01% 2706
2017
Q4
$141K Buy
8,458
+4,467
+112% +$75.6K ﹤0.01% 3131
2017
Q3
$79.9K Sell
3,991
-264
-6% -$5.17K ﹤0.01% 2905
2017
Q2
$78K Buy
4,255
+3,601
+551% +$48.5K ﹤0.01% 2943
2017
Q1
$6.43K Sell
654
-316
-33% -$3.83K ﹤0.01% 3263
2016
Q4
$10.6K Sell
970
-1,633
-63% -$17.1K ﹤0.01% 3425
2016
Q3
$36.5K Buy
2,603
+1,406
+117% +$11.4K ﹤0.01% 2576
2016
Q2
$8.4K Buy
+1,197
New +$8.78K ﹤0.01% 2996
2016
Q1
Sell
-3,933
Closed -$127K 2989
2015
Q4
$127K Sell
3,933
-3,203
-45% -$94.3K ﹤0.01% 1743
2015
Q3
$191K Buy
7,136
+4,320
+153% +$185K ﹤0.01% 1990
2015
Q2
$136K Buy
2,816
+2,232
+382% +$130K ﹤0.01% 1916
2015
Q1
$35.5K Buy
+584
New +$35.6K ﹤0.01% 2093
2014
Q4
Sell
-1,283
Closed -$56.5K 2908
2014
Q3
$56.5K Buy
1,283
+1,074
+514% +$33.6K ﹤0.01% 2518
2014
Q2
$5.46K Buy
209
+105
+101% +$2.25K ﹤0.01% 2538
2014
Q1
$2.03K Sell
104
-84
-45% -$2.26K ﹤0.01% 2655
2013
Q4
$3.19K Buy
+188
New +$3.3K ﹤0.01% 3388

Other funds holding PTCT

BNP Paribas Financial Markets's PTCT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its PTC Therapeutics (PTCT) stake by 59% in Q2 2026, selling an estimated $39.1M and leaving 378,720 shares worth $30.9M. The position accounts for 0.01% of the portfolio, ranked #1014.

BNP Paribas Financial Markets first reported a position in PTCT in Q4 2013 and has held it in 49 quarters since. The position peaked at $62.9M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • BNP Paribas Financial Markets held 378,720 shares of PTC Therapeutics worth $30.9M as of Q2 2026.
  • BNP Paribas Financial Markets sold 541,756 PTC Therapeutics shares in Q2 2026, an estimated $39.1M.
  • PTC Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1014 holding.
  • BNP Paribas Financial Markets first reported a position in PTC Therapeutics in Q4 2013 and has held it in 49 quarters since.
  • BNP Paribas Financial Markets's PTC Therapeutics position peaked at $62.9M in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.